Clinical Trial Update: Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) [Phase 1]

View source ↗

Summary

Clinical trial update for a pediatric glypican-3–targeted CAR-T therapy (GAP) in liver cancer; the Phase 1 study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Cancer

Drugs mentioned

• GPC3 CAR-T

Snippet

Sponsor: Baylor College of Medicine | Conditions: Liver Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING